MedPath

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Private
Established
1884-01-01
Employees
10K
Market Cap
-
Website
http://www.mskcc.org

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

Phase 2
Completed
Conditions
Malignant Pleural Mesothelioma
Interventions
First Posted Date
2009-12-03
Last Posted Date
2015-05-12
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
11
Registration Number
NCT01024946
Locations
πŸ‡ΊπŸ‡Έ

Dana Farber Cancer Institute, Boston, Massachusetts, United States

πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

πŸ‡ΊπŸ‡Έ

University of Pennsylvania, Philadelphia, Pennsylvania, United States

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Phase 1
Completed
Conditions
Squamous Cell Cancer
Head and Neck Cancer
Interventions
First Posted Date
2009-11-19
Last Posted Date
2019-06-26
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
48
Registration Number
NCT01016769
Locations
πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States

πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States

and more 2 locations

Percutaneous Renal Tumor Cryoablation Followed by Biopsy

Phase 1
Completed
Conditions
Renal Cancer
Interventions
Procedure: percutaneous cryoablation
First Posted Date
2009-11-13
Last Posted Date
2016-01-05
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
17
Registration Number
NCT01012427
Locations
πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas

Phase 2
Completed
Conditions
Brain Cancer
Interventions
Other: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
First Posted Date
2009-11-13
Last Posted Date
2022-03-14
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
47
Registration Number
NCT01012609
Locations
πŸ‡ΊπŸ‡Έ

Md Anderson Cancer Center, Houston, Texas, United States

πŸ‡ΊπŸ‡Έ

Phoenix Children'S Hospital, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

University of Colorado Health Sciences Center, Denver, Colorado, United States

and more 9 locations

Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age

Phase 2
Completed
Conditions
Chronic Lymphocytic Leukemia
Leukemia
Interventions
First Posted Date
2009-11-11
Last Posted Date
2017-05-18
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
26
Registration Number
NCT01011894
Locations
πŸ‡ΊπŸ‡Έ

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection

Active, not recruiting
Conditions
Melanoma
Interventions
Behavioral: screening questionnaire
First Posted Date
2009-10-30
Last Posted Date
2023-11-08
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
85
Registration Number
NCT01004952
Locations
πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Acupuncture for the Treatment of Chronic Lymphedema

Phase 2
Completed
Conditions
Breast Cancer
Lymphedema
Interventions
Procedure: Acupuncture
First Posted Date
2009-10-29
Last Posted Date
2012-08-16
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
37
Registration Number
NCT01003951
Locations
πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information

Completed
Conditions
Colon Cancer
Rectal Cancer
Interventions
Behavioral: Questionnaire
First Posted Date
2009-10-29
Last Posted Date
2014-12-02
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
177
Registration Number
NCT01003600
Locations
πŸ‡ΊπŸ‡Έ

Queens Cancer Center of Queens Hospital, Jamaica, New York, United States

πŸ‡ΊπŸ‡Έ

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Genomic Structural Variation in Cancer Susceptibility

Active, not recruiting
Conditions
Breast Cancer
Sarcoma
Colon Cancer
Germ Cell Cancer
Neuroblastoma
Rectal Cancer
First Posted Date
2009-10-16
Last Posted Date
2024-11-04
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
1275
Registration Number
NCT00996710
Locations
πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Phase 3
Completed
Conditions
Pancreatic Cancer
Interventions
First Posted Date
2009-10-14
Last Posted Date
2016-02-01
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
439
Registration Number
NCT00994110
Locations
πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Β© Copyright 2025. All Rights Reserved by MedPath